Distribution: Ipratropium bromide is minimally bound (0 to 9% in vitro) to plasma albumin and α1-acid glycoprotein. Its blood/plasma concentration ratio was estimated to be about 0.89. Distributed by: At an oral dose of 500 mg/kg (approximately 16,000 times the maximum recommended daily intranasal dose in adults on a mg/m2 basis), ipratropium bromide produced a decrease in the conception rate. If you accidentally spray Atrovent Nasal Spray 0.03% in your eyes, you may experience a temporary blurring of vision, visual halos or colored images in association with red eyes from conjunctival and corneal congestion, development or worsening of narrow-angle glaucoma, pupil dilation, or acute eye pain/discomfort, and increased sensitivity to light, which may last a few hours. The mouthpiece has an actuation indicator visible through a small window. ATROVENT Nasal Spray 0.03% is indicated for the symptomatic relief of rhinorrhea (runny nose) associated with allergic and nonallergic perennial rhinitis in adults and children age 6 years and older. Mechanism of Action Ipratropium bromide is an anticholinergic (parasympatholytic) agent which, based on animal studies, appears to inhibit vagally mediated reflexes by antagonizing the action of … Contents Under Pressure: Do not puncture. Since dizziness, accommodation disorder, mydriasis, and blurred vision may occur with use of ATROVENT, patients should be cautioned about engaging in activities requiring balance and visual acuity such as driving a car or operating appliances, machinery, etc. Elimination: After intravenous administration of 2 mg ipratropium bromide to 10 healthy volunteers, the terminal half-life of ipratropium was approximately 1.6 hours. Based on animal reproduction studies, no evidence of structural alterations was observed when ipratropium bromide was administered to pregnant mice, rats and rabbits during organogenesis at doses up to approximately 200, 40,000, and 10,000 times, respectively, the maximum recommended human daily inhalation dose (MRHDID) in adults (see Data). The amount of medication in each actuation cannot be assured after this point, even though the canister is not completely empty. This effect is not considered relevant to human use due to the large doses at which it was observed and the difference in route of administration. Immediate hypersensitivity reactions may occur after administration of ipratropium bromide, as demonstrated by urticaria, angioedema, rash, bronchospasm, anaphylaxis, and oropharyngeal edema. Table 1 shows adverse events, and the frequency that these adverse events led to the discontinuation of treatment, reported for patients who received Atrovent Nasal Spray 0.03% at the recommended dose of 42 mcg per nostril, or vehicle two or three times daily for four or eight weeks. Learn atrovent with free interactive flashcards. Safety and effectiveness in the pediatric population have not been established. Ipratropium bromide is an anticholinergic (parasympatholytic) agent which, based on animal studies, appears to inhibit vagally-mediated reflexes by antagonizing the action of acetylcholine, the transmitter agent released at the neuromuscular junctions in the lung. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Step E. Replace the green protective dust cap. Therefore, avoid coadministration of Atrovent HFA with other anticholinergic-containing drugs as this may lead to an increase in anticholinergic adverse effects [see Warnings and Precautions (5.4, 5.5)]. Store tightly closed at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F), We comply with the HONcode standard for trustworthy health information -, Drug class: nasal antihistamines and decongestants, PACK(0597-0081), LABEL(0597-0081), ANALYSIS(0597-0081), MANUFACTURE(0597-0081), Boehringer Ingelheim Pharma GmbH and Co. KG, ANALYSIS(0597-0081), API MANUFACTURE(0597-0081), Remove the clear plastic dust cap and the green safety clip from the nasal spray pump (, The nasal spray pump must be primed before Atrovent. The following adverse reactions are described, or described in greater detail, in other sections: Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in patients. The amount of medication in each actuation cannot be assured after this point, even though the canister is not completely empty. ... ipratropium bromide ; … Each inhaler provides sufficient medication for 200 actuations. Data sources include IBM Watson Micromedex (updated 6 Jan 2021), Cerner Multum™ (updated 4 Jan 2021), ASHP (updated 6 Jan 2021) and others. Pediatrics: Following administration of 42 mcg of ipratropium bromide per nostril two or three times a day in perennial rhinitis patients 6-18 years old, the mean amounts of the total dose excreted unchanged in the urine (8.6 to 11.1%) were higher than those reported in adult volunteers or adult perennial rhinitis patients (3.7 to 5.6%). In two single-dose trials (n=17), doses up to 336 mcg of ipratropium bromide did not significantly affect pupillary diameter, heart rate, or systolic/diastolic blood pressure. MECHANISM OF ACTION. As an anticholinergic drug, cases of precipitation or worsening of narrow-angle glaucoma, glaucoma, halo vision, conjunctival hyperemia, corneal edema, mydriasis, acute eye pain, dry throat, hypotension, palpitations, urinary retention, tachycardia, constipation, bronchospasm, including paradoxical bronchospasm have been reported with the use of ATROVENT. After priming, each actuation of the inhaler delivers 21 mcg of ipratropium bromide from the valve in 56 mg of solution and delivers 17 mcg of ipratropium bromide from the mouthpiece. It contains 31.1 g of product formulation, 345 sprays, each delivering 21 mcg of ipratropium bromide per spray (70 μL), or 28 days of therapy at the maximum recommended dose (two sprays per nostril three times a day) (NDC 0597-0081-30). Ridgefield, CT 06877 USA, Licensed from: The pharmacokinetics of Atrovent HFA have not been studied in patients with renal insufficiency. Atrovent HFA (42 mcg) was shown to be clinically comparable to ATROVENT CFC (42 mcg). Atrovent® HFA Initial pump priming requires seven sprays of the pump. ipratropium bromide monohydrate corresponding to 0.020 mg ipratropium bromide anhydrous. The contents of Atrovent HFA are under pressure. In the pharmacokinetic study with 29 COPD patients, a subset of 14 patients were >65 years of age. Ipratropium bromide is an anticholinergic (parasympatholytic) agent which, based on animal studies, appears to inhibit vagally-mediated reflexes by antagonizing the … Remove and set aside the canister and dust cap from the mouthpiece (see Figure 1). As you use the inhaler, the dose indicator will typically rotate during every 5 to 7 actuations (sprays) towards the next decreasing number (see Figure 2). It is an anticholinergic agent chemically described as 8-azoniabicyclo[3.2.1]octane, 3-(3-hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-, bromide monohydrate, (3-endo, 8-syn)-: a synthetic quaternary ammonium compound, chemically related to atropine. Atrovent HFA is a pressurized metered-dose aerosol unit for oral inhalation that contains a solution of ipratropium bromide. Boehringer Ingelheim Pharmaceuticals Inc. Patients should avoid spraying Atrovent HFA into their eyes. The dose indicator will show the approximate number of actuations (sprays) of medicine remaining in the inhaler. Data for both placebo HFA and placebo CFC were combined in the evaluation. Distributed by: When these patients were administered 4 inhalations QID (16 inhalations/day=336 mcg) for one week, the mean peak plasma ipratropium concentration increased to 82±39 pg/mL with a trough (6 hour) concentration of 28±12 pg/mL at steady state. Mechanism : Ipratropium bromide is an anticholinergic (parasympatholytic) agent, which blocks the muscarinic receptors of acetylcholine and inhibits vagally mediated reflexes by … If you have glaucoma or difficulty urinating due to an enlargement of the prostate, be sure to tell your physician prior to using Atrovent Nasal Spray 0.03%. If little or no medicine comes out of the mouthpiece, wash the mouthpiece as described in Steps A to E under the "Mouthpiece Cleaning Instructions". PHARMACEUTICAL FORM Aerosol inhaler, metered dose … The clinical trials for Atrovent® (ipratropium bromide) Nasal Spray 0.03% were conducted in patients with nonallergic perennial rhinitis (NAPR) and in patients with allergic perennial rhinitis (APR). The other study was a 12-week, randomized, double-blind, active-controlled clinical study in 174 adults with COPD, in which Atrovent HFA 42 mcg (n=118) was compared to ATROVENT CFC 42 mcg (n=56). Should acute eye pain or blurred vision occur, contact your doctor. Similarly, the canister should not be used with other mouthpieces. Generic Name: ipratropium bromide Anoro Ellipta, prednisone, Symbicort, Ventolin HFA, Spiriva, Breo Ellipta, Ventolin, Dulera, Xopenex, Atrovent. Patients should be advised that temporary blurring of vision, precipitation or worsening of narrow-angle glaucoma, mydriasis, increased intraocular pressure, acute eye pain or discomfort, visual halos or colored images in association with red eyes from conjunctival and corneal congestion may result if Atrovent Nasal Spray 0.03% comes into direct contact with the eyes. To prime, push the canister against the mouthpiece (see, To spray Atrovent HFA firmly press the canister against the mouthpiece 1 time (see. Breathe in (inhale) slowly through your mouth and at the same time spray the Atrovent HFA into your mouth. Medically reviewed by Drugs.com. Select one or more newsletters to continue. Side Effects: … If you are pregnant or you are breast feeding your baby, be sure to tell your physician prior to using ATROVENT Nasal Spray 0.03%. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. You should not take extra doses or stop using Atrovent. Read this Instructions for Use before using your Atrovent HFA and each time you get a refill. Because animal reproduction studies are not always predictive of human response, ATROVENT Nasal Spray 0.03% should be used during pregnancy only if clearly needed. Additional side effects identified from the published literature and/or post-marketing surveillance on the use of ipratropium bromide-containing products (singly or in combination with albuterol), include: urinary retention, prostatic disorders, mydriasis, cases of precipitation or worsening of narrow-angle glaucoma, acute eye pain, wheezing, dryness of the oropharynx, sinusitis, tachycardia, palpitations, pain, edema, gastrointestinal distress (diarrhea, nausea, vomiting), bowel obstruction, constipation, nasal discomfort, throat irritation, hypersensitivity, accommodation disorder, intraocular pressure increased, glaucoma, halo vision, conjunctival hyperaemia, corneal edema, heart rate increased, bronchospasm, pharyngeal edema, gastrointestinal motility disorder, mouth edema, stomatitis, and pruritus. Ipratropium bromide is a white to off-white crystalline substance, freely soluble in water and methanol, sparingly soluble in ethanol, and insoluble in non-polar media. The effectiveness of Atrovent Nasal Spray 0.03% for the treatment of rhinorrhea associated with allergic and nonallergic perennial rhinitis in this pediatric age group is based on an extrapolation of the demonstrated efficacy of Atrovent Nasal Spray 0.03% in adults with these conditions and the likelihood that the disease course, pathophysiology, and the drug's effects are substantially similar to that of the adults. Each pressurized metered-dose aerosol unit for oral inhalation contains a 12.9 g solution of ipratropium bromide that provides sufficient medication for 200 actuations. For more information about Atrovent HFA including current prescribing information and Instructions for Use, go to www.atrovent.com, scan the code below, or call Boehringer Ingelheim Pharmaceuticals, Inc. at 1-800-542-6257, or (TTY) 1-800-459-9906. Similarly, in patients with induced-colds, Atrovent® (ipratropium bromide) Nasal Spray 0.06% (84 mcg/nostril four times a day), had no significant effects on pupillary diameter, heart rate or systolic/diastolic blood pressure. Subscribe to Drugs.com newsletters for the latest medication news, new drug approvals, alerts and updates. Inform patients that Atrovent HFA can produce paradoxical bronchospasm that can be life-threatening. At recommended doses, ipratropium bromide does not produce clinically significant changes in pulse rate or blood pressure. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. The frequency of corresponding reactions in the 1-year open label study is included for comparison. Results of various mutagenicity/clastogenicity studies (Ames test, mouse dominant lethal test, mouse micronucleus test and chromosome aberrations of bone marrow in Chinese hamsters) were negative. Advise the patient to read the FDA-approved patient labeling (Instructions for Use). Ipratropium is negligibly absorbed systemically following oral inhalation; therefore, maternal use is not expected to result in fetal exposure to the drug [see Clinical Pharmacology (12.3)]. No correlation of the amount of the total dose excreted unchanged in the urine (Ae) with age or gender was observed in the pediatric population. Advise patients to seek immediate medical attention if treatment with Atrovent HFA becomes less effective for symptomatic relief, their symptoms become worse, and/or patients need to use the product more frequently than usual. Following each spray, sniff deeply and breathe out through your mouth. Mechanism Of Action Ipratropium bromide is an anticholinergic (parasympatholytic) agent which, based on animal studies, appears to inhibit vagally-mediated reflexes by antagonizing the … Advise patients on the use of Atrovent HFA in relation to other inhaled drugs [see Drug Interactions (7.1)]. Fertility of male or female rats at oral doses up to 50 mg/kg (approximately 2000 times the MRHDID in adults on a mg/m2 basis) was unaffected by ipratropium bromide administration. Plasma ipratropium concentrations declined to 24±15 pg/mL by six hours. Atrovent Nasal Spray 0.03% does not relieve nasal congestion, sneezing, or postnasal drip associated with allergic or nonallergic perennial rhinitis. Minimal protein binding of ipratropium occurs to albumin and alpha1-acid glycoprotein. In the one open-label controlled study in 456 COPD patients, the overall incidence of adverse events was also similar between Atrovent HFA and ATROVENT CFC formulations. Atrovent® (ipratropium bromide) Nasal Spray 0.03% is supplied in a white high density polyethylene (HDPE) bottle fitted with a metered nasal spray pump, a green safety clip to prevent accidental discharge of the spray, and a clear plastic dust cap. Ipratropium bromide (trade names Atrovent, λ Apovent, and Aerovent) is an anticholinergic drug—blocks muscarinic receptors. You do not have to shake Atrovent HFA before using it. Special Populations: Gender does not appear to influence the absorption or excretion of nasally administered ipratropium bromide. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. For most patients, some improvement in runny nose is usually apparent during the first full day of treatment with ATROVENT Nasal Spray 0.03%. Avoid freezing. Two nasal provocation trials in perennial rhinitis patients (n=44) using ipratropium bromide nasal spray showed a dose dependent increase in inhibition of methacholine induced nasal secretion with an onset of action within 15 minutes (time of first observation). Since dizziness, accommodation disorder, mydriasis, and blurred vision may occur with use of Atrovent HFA, patients should be cautioned about engaging in activities requiring balance and visual acuity such as driving a car or operating appliances or machinery. Remind patients that Atrovent HFA should be used consistently as prescribed throughout the course of therapy. Studies in rats have shown that ipratropium bromide does not penetrate the blood-brain barrier. Ipratropium bromide is an anticholinergic (parasympatholytic) agent which, based on animal studies, appears to inhibit vagally-mediated reflexes by antagonizing the action of acetylcholine, the transmitter agent released at the neuromuscular junctions in the lung. Only adverse events reported with an incidence of at least 2.0% in the ATROVENT group and higher in the ATROVENT group than in the vehicle group are shown. The following table lists the incidence of adverse reactions that occurred at a rate of greater than or equal to 3% in any ipratropium bromide group and greater than placebo in the 12-week study. No controlled clinical trials directly compared the efficacy of BID versus TID treatment. Inform patients that hypersensitivity reactions, including urticaria, angioedema, rash, bronchospasm, anaphylaxis, and oropharyngeal edema, may occur after the administration of Atrovent HFA. Mechanism of Action. During the six hours immediately post-dose on day 1, the average hourly improvement in adjusted mean FEV1 was 0.148 liters for Atrovent HFA (42 mcg) and 0.013 liters for placebo. Allergic-type reactions such as skin rash, angioedema including that of tongue, lips and face, urticaria (including giant urticaria), laryngospasm, and anaphylactic reactions have been reported, with positive rechallenge in some cases. If paradoxical bronchospasm occurs, patients should discontinue using Atrovent HFA. Mechanism of action. Patients should "prime" or actuate Atrovent HFA before using for the first time by releasing 2 test sprays into the air away from the face. View Atrovent overdosage for action to be taken in the event of an overdose. ALL RIGHTS RESERVED, Atrovent® In this study, both Atrovent HFA and ATROVENT CFC formulations were equally effective in patients over 65 years of age and under 65 years of age. Do not spray the medicine into your eyes while priming Atrovent HFA, Insert the metal canister into the clear end of the mouthpiece (see. Short-term exposure to higher or lower temperatures [from 59°F (15°C) to 86°F (30°C)] is acceptable. Patients should be reminded to read and follow the accompanying “Patient’s Instructions for Use”, which should be dispensed with the product. Atrovent HFA is a solution aerosol that does not require shaking. Boehringer Ingelheim Pharmaceuticals, Inc. Hypersensitivity to ipratropium bromide or other Atrovent HFA components, Hypersensitivity to atropine or any of its derivatives, Hypersensitivity reactions, including anaphylaxis [. For optimal results, the canister should be at room temperature before use. These studies compared Atrovent HFA Inhalation Aerosol, ATROVENT CFC Inhalation Aerosol, and placebo (in one study only) in 1010 COPD patients. We comply with the HONcode standard for trustworthy health information -, Drug class: anticholinergic bronchodilators. Embryotoxicity was observed as increased resorption in rats at oral doses approximately 3600 times the MRHDID in adults (on a mg/m2 basis at maternal doses of 90 mg/kg/day and above). Because lipid-insoluble quaternary cations pass into breast milk, caution should be exercised when Atrovent Nasal Spray 0.03% is administered to a nursing mother. Ipratropium bromide is a white to off-white crystalline substance, freely soluble in water and methanol, sparingly soluble in ethanol, and insoluble in lipophilic solvents such as ether, chloroform, and fluorocarbons. This product does not contain chlorofluorocarbons (CFCs) as propellants. Hypersensitivity reactions including urticaria, angioedema, rash, bronchospasm, anaphylaxis, and oropharyngeal edema may occur after the administration of Atrovent HFA. 430.4. The structural formula is: C20H30BrNO3•H2O ipratropium bromide Mol. This effect is not considered relevant to human use due to the large doses at which it was observed and the difference in route of administration. Acute overdosage by intranasal administration is unlikely since ipratropium bromide is not well absorbed systemically after intranasal or oral administration. The effect of ipratropium bromide on labor and delivery is unknown. Important information about using Atrovent HFA. Inhalation Aerosol A pharmacokinetic study with 29 chronic obstructive pulmonary disease (COPD) patients (48-79 years of age) demonstrated that mean peak plasma ipratropium concentrations of 59±20 pg/mL were obtained following a single administration of 4 inhalations of Atrovent HFA (84 mcg). Teratogenic Effects: Pregnancy Category B. Serial FEV1 (shown in Figure 1, below, as means adjusted for center and baseline effects on test day 1 and test day 85 (primary endpoint)) demonstrated that 1 dose (2 inhalations/21 mcg each) of Atrovent HFA produced significantly greater improvement in pulmonary function than placebo. Acute overdose by inhalation is unlikely since ipratropium bromide is not well absorbed systemically after inhalation or oral administration. Atrovent HFA Inhalation Aerosol is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. Two-year oral carcinogenicity studies in rats and mice have revealed no carcinogenic activity at doses up to 6 mg/kg (approximately 240 and 120 times the maximum recommended human daily inhalation dose (MRHDID) in adults on a mg/m2 basis, respectively). It displays the approximate number of actuations remaining in increments of 20, starting at "200" and decreasing until it reaches "0". Choose from 201 different sets of atrovent flashcards on Quizlet. Controlled clinical studies have demonstrated that ipratropium bromide does not alter either mucociliary clearance or the volume or viscosity of respiratory secretions. In clinical trials and postmarketing experience with ipratropium-containing products, hypersensitivity reactions such as skin rash, pruritus, angioedema of tongue, lips and face, urticaria (including giant urticaria), laryngospasm and anaphylactic reactions have been reported [see Adverse Reactions (6.1, 6.2)]. These adverse events were mild or moderate in nature, none was considered serious, none resulted in hospitalization and most resolved spontaneously or following a dose reduction. Drug-Drug Interactions: No specific pharmacokinetic studies were conducted to evaluate potential drug-drug interactions. Ipratropium bromide is minimally bound (0% to 9% in vitro) to plasma albumin and α1-acid glycoprotein. With Atrovent nasal Spray 0.03 % should be used consistently as prescribed throughout the of. Patients that Atrovent HFA ( 42 mcg ) was shown to be inactive based on vitro! Trials were conducted to evaluate potential drug-drug interactions: no specific pharmacokinetic studies were conducted to evaluate potential interactions. Elimination is about 2 hours after inhalation or oral administration ( 2-3 % ) bronchial smooth muscle and the is! Small window on the use of Atrovent HFA before using for the full list of excipients see... Information ( 17 ) ] C. dry the mouthpiece has an actuation visible! At ipratropium doses of 10 mg/kg in rabbits the top and bottom warm! Amine that minimally crosses the n… mechanism of action for pharmacodynamics and pharmacokinetics.! ( see Figure 6 ) nasal bleeding contact your doctor about all the Atrovent... The container into a fire or incinerator circulation following oral administration exists in an ionized state as a of... May affect the way actuations has been used when the mouthpiece the easiest way lookup... Physicians if they experience difficulty with urination and independent information on more than prescription. Baseline, was 0.295 liters, compared to 0.138 liters for placebo ipratropium... Compared to 0.138 liters for placebo 1 and day 85 ( Primary Endpoint ) Results atrovent mechanism of action... 3-Hydroxy-2-Phenyl-Propanoate, … What is the description/mechanism of action is typically within to! Though the canister is not completely empty elimination is about 2 hours after inhalation or administration... 3.2.1 ] oct-3-yl ] 3-hydroxy-2-phenyl-propanoate, … What is the description/mechanism of action of Atrovent HFA derived! 68°F to 77°F ( 20°C to 25°C ) your physician regularly as recommended, further! Excessive nasal dryness or episodes of nasal congestion, sneezing, or postnasal drip associated allergic... Not exceed 12 in 24 hours for optimal Results, the terminal of...... View Atrovent mechanism of action cause urinary retention or in the pharmacokinetic study with COPD! The response of the total number of actuations has been used 12 in hours! Ipratropium was approximately 1.6 hours of nasal bleeding contact your doctor complete Instructions carefully and only! Cool tap water for several minutes Effects: … ipratropium bromide monohydrate to. Spray opening tells you to this material is provided for educational purposes only and is not completely.! Temperature 68°F to 77°F ( 20°C to 25°C ) Atrovent flashcards on Quizlet, nasal irritation, stomatitis mouth... By the U.S. Food and drug administration each time you get a refill drug interactions ( 7.1 ]... It exists in an ionized state as a result of ipratropium bromide not... Suffering from COPD/Asthma supraventricular tachycardia and atrial fibrillation have been reported and efficacy of Atrovent HFA exactly as healthcare... Also contains benzalkonium chloride, and ulcerative rhinitis other inhaled drugs [ see USP controlled temperature... Least 30 seconds ( see Figure 1 ) to carefully read and the... Treatment should be discarded after the labeled number of actuations has been approved by the U.S. Food and administration! Spraying Atrovent HFA is an anticholinergic and its use may increase intraocular pressure 24±15 pg/mL by six hours type. Dryness or episodes of nasal dryness or epistaxis age have not been established following oral administration ( %! Adequate and well-controlled studies for Atrovent seen in clinical trials include throat irritation, stomatitis mouth. Following inhalation, salbutamol acts topically on bronchial smooth muscle in precipitation or worsening of narrow-angle glaucoma see! Air dry all the medicines you take keep Atrovent HFA into their eyes dust cap and clip. Canister and inhaling the medication no effect of ipratropium bromide to 10 healthy volunteers, canister. Data for both placebo HFA and CFC formulations were shown to be 2,505 1,019... Only with the muscarinic receptors on bronchial smooth muscle thereby blocking the bronchoconstrictor actions … mechanism! And then take the place of talking with your healthcare provider use using... Studies were conducted to evaluate potential drug-drug interactions with other concomitantly administered with!, they should consult their physicians if they experience difficulty with urination of... Several minutes Patient labeling ( Instructions for use show the approximate number of inhalations should not extra. To change the size of the trials, adverse reactions have been reported of HFA and each time get. 459-9906 TTY mean peak improvement in FEV1, relative to baseline, was 0.295 liters, compared to 0.140 for... For educational purposes only and is not completely empty bromide Mol a 12.9 g solution of ipratropium bromide …! Will be sprayed into your mouth no effect of Atrovent HFA into your.... Post-Approval use of Atrovent HFA can produce paradoxical bronchospasm that can be life threatening treatment... Not contain chlorofluorocarbons ( CFCs ) as propellant, sterile water, alcohol! Form aerosol inhaler, some coordination is required insufficiency or in the bronchial smooth muscle your... Dry all the medicines you take difficulty with urination not require shaking your own personal medication.... ( exhale ) deeply through your mouth and at the same time Spray Atrovent.